Press release
NASH/MASH Treatment Market Opportunity in Obesity-Co-Morbidity Therapies and GLP 1 Combo Approaches
NASH/MASH Treatment Market
As per our analysis, the NASH/MASH Treatment Market is spearheaded by Madrigal Pharmaceuticals (with its first-in-class drug resmetirom/Rezdiffra). Emerging biotech contenders include Novo Nordisk, Boehringer Ingelheim, 89bio, Inventiva, Chia Tai Tianqing, Sagimet Biosciences, and Akero Therapeutics, focusing on advanced small molecules, RNAi agents, PPAR agonists, and liver fibrosis inhibitors. Together, they foster a dynamic market with strong R&D innovation and regulatory breakthroughs.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market?jd
NASH/MASH Treatment Market M&A & Strategic Collaborations
• Madrigal secures U.S. patent for Rezdiffra until 2044, strengthening its market exclusivity in NASH/MASH therapy.
• Inventiva's Lanifibranor maintains Phase III momentum under Breakthrough status, supported by recent pipeline reports.
• Madrigal completes patient enrollment in cirrhosis trial (Phase III), advancing its MASH indication.
These highlights demonstrate a surge in patent fortification, Phase III data progression, and clinical expansion in the NASH/MASH market rather than traditional M&A.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nash-or-mash-treatment-market?jd
Key Growth Drivers & Emerging Opportunities in the NASH/MASH Treatment Market
• Rezdiffra enjoys blockbuster launch, with Q1 2025 sales of USD 137.3 million and over 17,000 patients treated.
• Strong pipeline advancement: Pan-PPAR agonist lanifibranor (Breakthrough/FTD in Phase III) and RNAi/ASO candidates (ARO-HSD, AZD2693) progress.
• Rising NASH prevalence, linked to obesity and diabetes, supports robust therapeutic demand.
• Biotech-biologic partnerships accelerate commercialization of next-gen targets (e.g., fibrosis, metabolic endpoints, GLP-1 combos).
• Strategic patent positioning and EU conditional approvals expand addressable patient populations globally.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nash-or-mash-treatment-market?jd
Regional Market Drivers in the NASH/MASH Treatment Market
North America leads, propelled by Rezdiffra's FDA approval, widespread NASH screening, and payer adoption.
Europe builds groundwork via EMA conditional authorization of Resmetirom and late-stage trial entries.
Asia-Pacific emerges with RNAi therapies, biosimilars, and obesity-linked disease management fueling pipeline interest.
LATAM & MEA show expansion due to rising metabolic disorder prevalence and increasing trial participation in emerging disease areas.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis for Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NASH/MASH Treatment Market Opportunity in Obesity-Co-Morbidity Therapies and GLP 1 Combo Approaches here
News-ID: 4108520 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Global Clinical Chemistry Market - Size, Share, and Forecast (2025-2033) By Data …
Market Overview
The global clinical chemistry market is a vital component of diagnostic medicine, fueled by the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and liver and kidney conditions. Valued at US$ 15.43 billion in 2023, the market grew to US$ 16.63 billion in 2024 and is projected to reach US$ 34.31 billion by 2033, achieving a CAGR of 8.4% during the forecast period 2025-2033. This growth is…
Radiopharmaceuticals Market Size to Reach US$ 19.69 Billion by 2033 - Exclusive …
Radiopharmaceuticals Market Size
The global radiopharmaceuticals market was valued at US$ 7.91 billion in 2024, up from US$ 7.20 billion in 2023, and is projected to reach US$ 19.69 billion by 2033, growing at a CAGR of 10.8% during the forecast period 2025-2033.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response)
https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market?jn
Market Overview
The radiopharmaceuticals market is expanding rapidly, fueled by increasing demand for precision…
NGS-Based RNA Sequencing Market Size to Reach Significant Growth by 2031 - Exclu …
Market Overview
According to DataM Intelligence, the global NGS-based RNA Sequencing Market reached a notable valuation in 2023 and is projected to grow at a CAGR of 19.7% during the forecast period 2024-2031. The market is driven by advancements in next-generation sequencing (NGS) technologies, enabling faster, cost-effective, and high-throughput RNA sequencing for transcriptomics and gene expression studies.
The market is propelled by increasing product approvals, automation in sample preparation, and growing genomic…
Japan Point-of-Care Diagnostics Market to Surpass USD 1,925.62 Million by 2033, …
The Japan point-of-care (POC) diagnostics market is experiencing robust growth, driven by the increasing demand for rapid, accessible, and accurate diagnostic solutions that enable timely medical interventions. This market encompasses a wide range of portable and user-friendly diagnostic devices used at or near the patient's location, such as glucose monitors, infectious disease testing kits, and cardiac marker tests, which deliver results within minutes. Japan, with its advanced healthcare infrastructure and…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
